Torrent Pharmaceuticals reports a strong quarter-to-quarter jump in revenue but slower profit growth, attributing the muted earnings to a one-time loss. In Q1, revenue from operations rises 54.8% year-on-year to Rs 4,921 crore, up from Rs 3,178 crore in the same period last year. The company’s results indicate broad strength across its business lines as revenue growth accelerates. However, profit growth does not match the pace of sales, with the company pointing to a one-time loss as a key factor affecting profitability in the quarter. Across the sources provided, the emphasis is on the disparity between high top-line growth and tempered earnings performance. The reporting centers on these headline financial movements—revenue expanding sharply while profit increases are described as muted due to the non-recurring impact. The accounts do not provide further breakdowns or additional quantitative details beyond the revenue figure and the explanation for profit growth.